+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10002(MPZL1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10002(MPZL1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

MPZL1 (Myelin Protein Zero-like 1), also known as PZR, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It shares structural homology with Myelin Protein Zero (MPZ), a key component of peripheral nerve myelin. MPZL1 is widely expressed in various tissues, including the liver, breast, and immune cells, and plays roles in cell adhesion, signaling, and immune regulation. Studies suggest its involvement in modulating receptor tyrosine phosphatase activity, particularly interacting with SHP-2 to influence downstream pathways like MAPK/ERK, which are critical for cell proliferation and differentiation.

MPZL1 antibodies are essential tools for investigating its biological functions and disease associations. Research highlights its dual role in cancer: MPZL1 overexpression correlates with poor prognosis in hepatocellular carcinoma and breast cancer, promoting tumor growth and metastasis, while acting as a tumor suppressor in certain contexts. Antibodies targeting MPZL1 enable detection of its expression levels via techniques like Western blot, immunohistochemistry, and flow cytometry, aiding in mechanistic studies and biomarker discovery. Dysregulation of MPZL1 has also been linked to autoimmune disorders and hearing loss, emphasizing its broad pathophysiological relevance. The development of specific MPZL1 antibodies continues to support advances in understanding its complex roles in cellular communication and disease pathogenesis.